Al-Dourobi Karim, Laurent Alexis, Deghayli Lina, Flahaut Marjorie, Abdel-Sayed Philippe, Scaletta Corinne, Michetti Murielle, Waselle Laurent, Simon Jeanne-Pascale, Ezzi Oumama El, Raffoul Wassim, Applegate Lee Ann, Hirt-Burri Nathalie, Roessingh Anthony S de Buys
Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Lausanne Burn Center, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Pharmaceuticals (Basel). 2021 Feb 28;14(3):201. doi: 10.3390/ph14030201.
Progenitor Biological Bandages (PBB) have been continuously applied clinically in the Lausanne Burn Center for over two decades. Vast translational experience and hindsight have been gathered, specifically for cutaneous healing promotion of donor-site grafts and second-degree pediatric burns. PBBs constitute combined Advanced Therapy Medicinal Products, containing viable cultured allogeneic fetal dermal progenitor fibroblasts. Such constructs may partly favor repair and regeneration of functional cutaneous tissues by releasing cytokines and growth factors, potentially negating the need for subsequent skin grafting, while reducing the formation of hypertrophic scar tissues. This retrospective case-control study (2010-2018) of pediatric second-degree burn patients comprehensively compared two initial wound treatment options (i.e., PBBs versus Aquacel Ag, applied during ten to twelve days post-trauma). Results confirmed clinical safety of PBBs with regard to morbidity, mortality, and overall complications. No difference was detected between groups for length of hospitalization or initial relative burn surface decreasing rates. Nevertheless, a trend was observed in younger patients treated with PBBs, requiring fewer corrective interventions or subsequent skin grafting. Importantly, significant improvements were observed in the PBB group regarding hypertrophic scarring (i.e., reduced number of scar complications and related corrective interventions). Such results establish evidence of clinical benefits yielded by the Swiss fetal progenitor cell transplantation program and favor further implementation of specific cell therapies in highly specialized regenerative medicine.
祖细胞生物绷带（PBB）在洛桑烧伤中心已持续临床应用二十多年。积累了丰富的转化经验和事后分析结果，特别是在促进供皮区移植皮肤和小儿二度烧伤的皮肤愈合方面。PBB是组合式先进治疗药品，包含有活力的培养异体胎儿真皮祖细胞成纤维细胞。这类构建物可能通过释放细胞因子和生长因子，部分促进功能性皮肤组织的修复和再生，有可能无需后续皮肤移植，同时减少肥厚性瘢痕组织的形成。这项针对小儿二度烧伤患者的回顾性病例对照研究（2010 - 2018年）全面比较了两种初始伤口治疗方案（即PBB与水凝胶银敷料，在创伤后十至十二天应用）。结果证实了PBB在发病率、死亡率和总体并发症方面的临床安全性。两组在住院时间或初始相对烧伤面积减少率方面未检测到差异。然而，观察到接受PBB治疗的较年轻患者有一个趋势，即需要更少的矫正干预或后续皮肤移植。重要的是，PBB组在肥厚性瘢痕形成方面有显著改善（即瘢痕并发症数量和相关矫正干预减少）。这些结果证实了瑞士胎儿祖细胞移植项目产生的临床益处，并有利于在高度专业化的再生医学中进一步实施特定的细胞疗法。
